SEGMENTS

6 Months Ended

Jun. 30, 2022

SEGMENTS [Abstract]

SEGMENTS

11. SEGMENTS

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.  The Company’s ADMA BioManufacturing segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1).  The Plasma Collection Centers segment as of June 30, 2022 consists of ten plasma collection facilities located throughout the U.S., six of which hold FDA licenses, with two additional plasma collection centers in operation and collecting plasma and the remaining two facilities under construction. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended June 30, 2022
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	32,120,119		$	1,749,179		$	35,709		$	33,905,007
Cost of product revenue		24,287,122			1,848,492			-			26,135,614
Loss from operations		(445,248	)		(4,020,799	)		(4,708,692	)		(9,174,739	)
Interest and other expense, net		(17,796	)		(336	)		(4,572,035	)		(4,590,167	)
Net loss		(463,044	)		(4,021,135	)		(9,280,727	)		(13,764,906	)
Total assets		220,052,465			34,078,909			42,800,955			296,932,329
Depreciation and amortization expense		1,159,732			564,396			155			1,724,283

Three Months Ended June 30, 2021
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	16,347,880		$	1,447,001		$	35,709		$	17,830,590
Cost of product revenue		17,382,292			1,450,332			-			18,832,624
Loss from operations		(8,337,405	)		(2,794,219	)		(4,449,608	)		(15,581,232	)
Interest and other expense, net		(78,793	)		(366	)		(3,244,912	)		(3,324,071	)
Net loss		(8,416,198	)		(2,794,585	)		(7,694,520	)		(18,905,303	)
Total assets		169,799,509			20,593,411			42,420,872			232,813,792
Depreciation and amortization expense		1,055,537			268,927			1,530			1,325,994

Six Months Ended June 30, 2022
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	57,848,744		$	5,087,939		$	71,417		$	63,008,100
Cost of product revenue		46,500,902			5,075,758			-			51,576,660
Loss from operations		(4,720,538	)		(7,883,894	)		(11,385,373	)		(23,989,805	)
Interest and other expense, net		(67,062	)		(1,066	)		(8,044,889	)		(8,113,017	)
Loss on extinguishment of debt		-			-			(6,669,941	)		(6,669,941	)
Net loss		(4,787,600	)		(7,884,960	)		(26,100,203	)		(38,772,763	)
Capital expenditures		2,584,906			4,197,263			-			6,782,169
Depreciation and amortization expense		2,271,683			1,041,899			918			3,314,500

Six Months Ended June 30, 2021
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	29,768,923		$	4,038,868		$	71,417		$	33,879,208
Cost of product revenue		32,832,049			3,770,697			-			36,602,746
Loss from operations		(17,843,093	)		(4,765,060	)		(8,137,328	)		(30,745,481	)
Interest and other expense, net		(100,307	)		(750	)		(6,438,706	)		(6,539,763	)
Net loss		(17,943,400	)		(4,765,810	)		(14,576,034	)		(37,285,244	)
Capital expenditures		2,725,432			4,321,303			-			7,046,735
Depreciation and amortization expense		2,065,307			486,918			3,397			2,555,622

Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
United States	$	31,274,844	$	15,424,839	$	58,590,995	$	29,102,848
International		2,630,163		2,405,751		4,417,105		4,776,360
Total revenues	$	33,905,007	$	17,830,590	$	63,008,100	$	33,879,208